A Phase 2 Study of Letermovir Treatment for Patients Experiencing Refractory or Resistant Cytomegalovirus Infection or Disease With Concurrent Organ Dysfunction
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Letermovir (Primary) ; Letermovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 05 Nov 2019 Planned End Date changed from 1 Dec 2020 to 1 Jul 2021.
- 05 Nov 2019 Planned primary completion date changed from 1 Jul 2020 to 31 Dec 2020.
- 11 Jan 2019 Status changed from not yet recruiting to recruiting.